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a b s t r a c t
To evaluate the current evidence that support or disprove the use of glucosamine and 
chondroitin in the treatment of patients with osteoarthritis. We performed a literature 
review using the databases of Medline, PubMed and the Cochrane Controlled Trial Register 
and Cochrane Databases Systematic Reviews (Cochrane Library). We considered only studies 
with high level of evidence. The study included analysis of randomized controlled trials that 
included at least 100 patients in each intervention group, meta-analyzes and systematic 
reviews. Seven meta-analysis, one systematic review and five randomized clinical trials 
fit inclusion criteria of this review. Considering the best evidences until now, the use of 
glucosamine and chondroitin does not provide clinical relevant benefits to patients with 
osteoarthritis of the knee or hip (Level I of evidence and grade A of recommendation). 
Further trials with adequate technology are necessaries to elucidate this question. 
© 2013 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora 
Ltda. 
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Revisão
r e s u m o
Avaliar evidências que apoiem ou refutem o uso de glucosamina e condroitina no 
tratamento de pacientes com osteoartrose. Foi feita uma revisão da literatura com o uso 
dos bancos de dados Medline, Pubmed e Cochrane Controlled Trial Register e Cochrane 
Databases Systematic Reviews (Cochrane Library). Foram considerados apenas estudos com 
elevado nível de evidências. O estudo incluiu a análise de ensaios clínicos randomizados 
que incluíram pelo menos 100 pacientes em cada grupo de intervenção, metanálises e 
revisões sistemáticas. Sete metanálises, uma revisão sistemática e cinco ensaios clínicos 
randomizados preencheram os critérios de inclusão desta revisão. Frente às melhores 
evidências existentes até o momento, o uso da glucosamina sulfatada/hidroclorídrica e da 
condroitina não produz benefícios clinicamente relevantes em pacientes com osteoartrose 
do joelho e do quadril (nível de evidência I e grau de recomendação A). Futuros estudos com 
metodologia adequada são necessários para elucidação dessa questão.  
© 2013 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado pela Elsevier Editora 
Ltda. 
Uso de glucosamina e condroitina no tratamento da osteoartrose: uma 
revisão da literatura
Introduction
Osteoarthrosis, also known as arthrosis or osteoarthritis, 
is the most frequent form of arthritis and is one of the 
main causes of limitation and reduction of quality of life 
among the population over the age of 50 years. The need 
for financial resources directed towards osteoarthrosis 
treatment is increasing year by year because of increasing 
prevalence of osteoarthrosis. These increases are caused 
mainly by greater life expectancy among the population, 
which has given rise to higher incidence of degenerative 
joint diseases.1
It has been estimated that more than 75% of people 
over the age of 65 years present osteoarthrosis in one or 
more joints.2 American studies have shown that 12.1% of 
individuals over the age of 25 years present clinical signs 
and symptoms of osteoarthrosis and that 6% and 3% of 
individuals over the age of 30 years present osteoarthrosis 
symptoms in the knees and hips, respectively.3 Currently, 
in Brazil, there are no epidemiological studies depicting the 
prevalence of osteoarthrosis or any data on the amount of 
public funding used for treating this pathological condition. 
Even so, with the proportion of elderly people over the age 
of 60 years at around 9.9% and life expectancy of around 
another 21.3 years, osteoarthrosis needs to be considered to 
be a disease of public health interest in Brazil.4
Osteoarthrosis is characterized by degradation of the 
joint cartilage. This clinical condition is composed of pain, 
stiffness, joint effusion and joint deformities. Biological, 
genetic, biochemical, nutritional and mechanical factors 
contribute towards the etiology of osteoarthrosis.3,5
Osteoarthrosis causes destruction of the cartilage with 
subsequent loss of the joint space. However, it should be 
considered to be a disease of the entire joint, involving the 
cartilage, ligaments, synovia and bone. From a supposed 
genetic component, it is believed that primary osteoarthrosis 
is triggered by mechanical overloading of the cartilage, which 
gives rise to a vicious circle of inflammation and degradation 
of the joint cartilage. The primary agents for this inflammatory 
pathway are interleukin-1 (IL-1) and tumor necrosis factor 
(TNF), which induce greater expression of metalloproteinases 
and nitric oxides (NO), which are the main catabolic agents 
involved in joint cartilage lesions.5,6,7
Currently, there is no consensus regarding the ideal 
treatment for osteoarthrosis. Several treatment methods have 
been used with the aims of pain relief and improvement of 
patients’ functional abilities. Among these, pharmacological 
methods, non-pharmacological methods (physiotherapy, 
occupational therapy, weight loss and exercise), physical 
agents, alternative therapies (homeopathy, acupuncture and 
phytotherapeutic medications) and surgical methods can be 
highlighted. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
considered by many authors to be the first-choice medications 
for pharmacological treatment of osteoarthrosis.8,9 Use of 
NSAIDs has been shown to be effective for pain relief and for 
improvement of function among patients with osteoarthrosis. 
However, it needs to be taken into consideration that NSAIDs 
are medications that treat the symptoms and that they have 
not been correlated with modification of the natural history of 
osteoarthrosis. Moreover, the main limitation on chronic use 
of NSAIDs comes from the potential adverse effects on the 
gastrointestinal and cardiovascular systems, which are found 
mainly among elderly patients.10 
Este é um artigo Open Access sob a licença de CC BY-NC-ND  
302 rev bras ortop. 2013;48(4):300-306
Recently, new medications have been considered in 
treatments for osteoarthrosis. Within this new context, 
glucosamine and chondroitin have emerged as biological 
alternatives to drug treatment. Even without strong scientific 
evidence, both of these medications have been seen as 
substances that modify the natural history of osteoarthrosis.11
It is believed that glucosamine participates as a substrate 
in synthesizing glycosaminoglycans (GAGs), proteoglycans and 
hyaluronate in the joint cartilage. It also acts on chondrocytes 
through stimulating proteoglycan synthesis and inhibiting 
metalloproteinase synthesis. Use of glucosamine is based 
on studies done on animal models and in vitro studies 
that showed that the joint metabolism became normalized 
during the healing of chondral lesions, along with slight anti-
inflammatory action.12,13 There are three types of glucosamine 
available on the market: glucosamine hydrochloride (taken 
from crab shells), glucosamine sulfate (taken from shrimp 
shells) and synthetic glucosamine (sulfate). Some studies have 
shown that glucosamine is more efficient than placebo for 
improving symptoms and that it can also diminish the speed 
of progression of joint narrowing in osteoarthrosis.14-19
Chondroitin is a glycosaminoglycan (GAG) that is found 
in several types of tissue, including hyaline cartilage. Recent 
studies have concluded that chondroitin stimulates synthesis 
of cartilage, and also acts towards inhibiting IL-1 and 
metalloproteinases.20 There is also evidence to indicate that 
chondroitin is better than placebo for alleviating symptoms, 
but that it is not effective for diminishing the progression of 
joint narrowing. 
In using an association of glucosamine and chondroitin, 
an initial plasma peak is presented around two hours after 
ingestion of the medication and a second peak 18 hours 
afterwards, which indicates that enterohepatic circulation 
exists. Oral use of glucosamine in a single dose of 1,500 mg 
produces a plasma concentration of approximately 10 μmol, 
while use of 500 mg taken three times a day generates a 
concentration of only 3 μmol. The recommended dose of 
chondroitin is 1,200 mg per day. In addition, it is believed that 
the association of glucosamine/chondroitin administered orally 
is absorbed satisfactorily by means of a saturable mechanism, 
which is important in clinical practice.21 
The potential synergic effects from associating glucosamine 
and chondroitin are still being studied. One recent study did not 
find any evidence that associating the medications promoted 
improvement of the symptoms in comparison with placebo, 
for treating patients with osteoarthrosis.22 
The present review had the aim of evaluating the current 
evidence supporting or rejecting glucosamine and chondroitin 
use for treating patients with osteoarthrosis. 
Materials and methods
A review of the literature was conducted using the Medline 
and PubMed databases, the Cochrane Controlled Trial 
Register and the Cochrane Database of Systematic Reviews 
(Cochrane Library). The search used the following keywords: 
glucosamine,chondroitin, osteoarthritis, randomized, controlled and 
metaanalysis . Only studies defined as presenting high quality of 
evidence were included (level A, according to the Oxford Centre 
for Evidence Based Medicine),23 i.e. systematic reviews, meta-
analyses and randomized controlled clinical trials (RCTs). The 
population of interest included patients with knee and/or hip 
osteoarthrosis who were undergoing nonsurgical treatment for 
painful osteoarthrosis.
Inclusion criteria for articles
Only studies defined as presenting high quality of evidence 
were included (level A, according to the Oxford Centre for 
Evidence Based Medicine):23 
- Systematic reviews or meta-analyses on RCTs that 
evaluated the use of glucosamine/chondroitin in humans with 
knee and/or hip osteoarthrosis;
- Controlled RCTs that compared the use of glucosamine/
chondroitin with placebo or another medication, with a 
minimum of 24 weeks of follow-up;
- Adequately designed studies that included at least 100 
patients in each intervention (glucosamine, chondroitin, 
glucosamine/chondroitin and placebo).
- Studies in which the primary outcome was assessment 
of pain intensity and the secondary outcome was assessment 
of the diminution of the joint space by means of radiographs 
on the knee.
Exclusion criteria for articles
- Studies on animals; 
- Studies that evaluated the temporomandibular joint.
Results
Out of the 413 potentially eligible studies investigated in Medline 
and PubMed (keywords: it AND chondroitin), only 13 studies 
included the word meta-analysis. Among the 13 meta-analyses 
evaluated in detail, only eight studies, including one systematic 
review from the Cochrane Collaboration, fulfilled the inclusion 
criteria with high quality of evidence presented.15,17,18,24-27 
Moreover, out of the 58 potentially eligible RCTs, only five 
fulfilled the inclusion criteria and were thus selected for 
compiling the present review.19,22,28-31 All the RCTs included 
presented adequate design and high quality of evidence. In the 
end, 11 studies fulfilled the inclusion criteria for compiling the 
systematic review. The abstracts and comments on the studies 
evaluated are shown in Tables 1 and 2.
Discussion
Osteoarthrosis is the commonest form of arthritis and is 
one of the most frequent causes of morbidity among the 
population over the age of 50 years. The knee and hip are 
among the joints most affected and, because these are 
considered to be load-bearing joints, their involvement 
certainly gives rise to a high degree of functional limitation 
of the lower limbs. With increasing life expectancy among the 
Brazilian population, treatment of degenerative joint diseases 
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Study (ref#) Level of evidence Type of study Parameters evaluated Results and conclusions
[24] 1A
Meta-analysis (10 RCTs) 
N = 3,803 
GS/GH, CS vs placebo
Pain (VAS) GS/ GH and CS did not reduce pain and did 
not have any impact on narrowing of the joint 
space.
[15] 1A
Systematic review (25 
RCTs) 
GS vs placebo
Pain/Function 
Structural effects
The studies without conflicts of interest did 
not demonstrate any benefits from using GS.
[25] 1A
Meta-analysis
15 studies
GH, GS
Pain
Heterogenous studies.
Conflicts of interest.
Greater effects in studies with conflicts of 
interest.
[31] 1A
Meta-analysis
6 systematic reviews
1 guideline GS/GH, CS
Pain
Joint space
Cost effectiveness
GS presented better clinical results. 
Cost effectiveness not detailed clearly.
[26] 1A
Meta-analysis (6 RCTs) 
N = 1,502 
GS and CS
Joint space
GS and CS delayed the progression of 
osteoarthrosis after 2-3 years. Slight effects.
[27] 1A
Meta-analysis 20 RCTs 
N = 3,846 
CS vs placebo
Pain
Majority of the studies presented delineation 
errors.
CS did not present any benefits.
[18] 1A
Meta-analysis
15 RCTs
GS and CS
Pain/Different parameters 
evaluated
Only one study presented clarity regarding 
allocation. Majority of the studies presented 
conflicts of interest. GS/CS was effective for 
pain control and improvement of function.
[17] 1A
Meta-analysis 
GS and CS
Joint space
Functional scores
GS was effective with regard to all the 
parameters evaluated; CS was not shown to be 
effective in delaying the radiological evolution. 
Further studies are needed.
CS, chondroitin sulfate; RCT, randomized clinical trial; GH, glucosamine hydrochloride; GS, glucosamine sulfate; VAS, pain assessment using a 
visual analogue scale. 
Cochrane: review published in the Cochrane Library. NSAIDs, non-steroidal anti-inflammatory drugs.
Study (ref#) Level of evidence Type of study Parameters evaluated Results and conclusions
[22] 1A
RCT, controlled, DB  
N = 1,583 
GH, CS, GH+CS, 
celecoxib, 
placebo Expected 
improvement effect
WOMAC with pain
Evaluation after 4, 8, 16  
and 24 months
GH, CS or GH+CS did not reduce the pain in 
patients with osteoarthrosis.
GH+CS was able to diminish the pain in 
patients with moderate to severe arthrosis.
[19] 1A
RCT, controlled, DB
N = 212
GS 1,500 mg/day/3 
years vs placebo
Allocation not 
detailed
Medial joint space
WOMAC
GS smaller loss of joint space (p = 0.043).
Slight clinical improvement (p = 0.020).
Irrelevant clinical difference.
Conflicts of interest.
[19] 1A
RCT, controlled, DB 
N = 202
GS 1,500 mg/day/3 
years vs placebo
Medial joint space
Womac
Lequesne
GS smaller loss of joint space (p = 0.001).
Slight clinical improvement 20-25%.
Irrelevant clinical difference.
Conflicts of interest.
[29] 1A
RCT, controlled, DB 
N = 186
GS 1,500 mg/day/12 
weeks vs placebo
WOMAC
PAIN AND STIFFNESS
FUNCTIONAL SCORE
GS and placebo without difference.
Short follow-up.
[30] 1A
RCT, controlled, DB 
N = 622
CS 800 mg/day/24 
weeks vs placebo
Pain
Medial joint space
CS promoted improvement of pain and smaller 
loss of medial joint space.
CS, chondroitin sulfate; DB, study with double blinding, RCT, randomized clinical trial; GH, glucosamine hydrochloride; 
*GS, glucosamine sulfate; Womac, Western Ontario and McMaster Universities Osteoarthritis Index. Lequesne; scores used for functional 
evaluation in patients with osteoarthrosis.
Table 1 - Summary of the systematic reviews and meta-analysis studies evaluated.
Table 2 - Summary of the RCTs evaluated.
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should be considered to be a matter of public health interest. 
In Brazil, there is no precise data regarding the prevalence 
of osteoarthrosis or the estimated cost of treatment and the 
social security expenditure resulting from the complications of 
osteoarthrosis. In the United States, in 2004, US$ 86 billion were 
allocated to osteoarthritis treatment. The sale of medications 
and supplements for osteoarthrosis has a turnover of US$ 760 
million.32
The clinical treatment for osteoarthrosis is still a matter 
for debate. Even after many years of research and investment, 
doubts still exist regarding the efficacy of using glucosamine 
and chondroitin as medications for modifying the natural 
history of osteoarthrosis. Most studies published so far lack 
delineation good enough to draw secure conclusions.
McAlindon et al.18 evaluated 15 RCTs that analyzed the 
benefit of using glucosamine and chondroitin for treating 
knee and hip osteoarthrosis. They concluded that glucosamine 
and chondroitin produced at least moderate effects, but that 
the quality of the published papers was insufficient and 
the quantification of the effects presented was generally 
exaggerated. Only one of the studies included had an adequate 
description of the randomization methods and only two 
included intention-to-treat analysis. Another noteworthy 
point was that most of the studies had been funded by the 
pharmaceutical industry. The effect of the medication was only 
less when only the large well-designed trials were taken into 
consideration.
Lee et al.26 evaluated 1,502 patients in a meta-analysis. The 
primary outcome of the study was diminished medial knee 
joint space. It was concluded that glucosamine sulfate and 
chondroitin sulfate delayed the progression of gonarthrosis 
through lower loss of joint space after three years of using the 
medication. The effect found was less with use of chondroitin. 
It needs to be emphasized that in this study, functional 
improvement and pain reduction were not evaluated. In a 
critical interpretation, it needs to be borne in mind that even 
with a statistically significant difference in favor of using the 
medication, this may not be related to a clinically relevant 
outcome if the radiological progression of arthrosis is taken 
into consideration.
Reichenbach et al.27 evaluated the use of chondroitin 
sulfate alone in 20 studies with a total of 3,846 patients. They 
concluded that use of chondroitin alone was not associated 
with pain reduction and functional improvement. However, a 
large proportion of the studies presented methodological flaws.
Vlad et al.25 demonstrated that most of the studies on 
this subject presented conflicts of interest and were too 
heterogenous to be evaluated together. The positive effects 
were greater in the studies funded by the pharmaceutical 
industry. Richy et al.17 showed that glucosamine sulfate 
and chondroitin sulfate improved function and delayed the 
progression of arthrosis, but they stated that new studies with 
appropriate methodology are needed in order to confirm the 
results.
Towheed et al.15 published an important systematic review 
in the Cochrane Library in 2009. The review evaluated 25 
studies that compared the use of glucosamine with placebo 
for treating osteoarthrosis and concluded that, up to the time 
of publication, there was no strong evidence that would justify 
using glucosamine to treat osteoarthrosis. It included studies 
that assessed overall pain, function, mobility, reduction of 
joint space and patient satisfaction with the treatment. In this 
review, 56% of the studies had some form of relationship with 
the pharmaceutical industry. The authors emphasized that if 
the evaluation only included the studies without conflicts of 
interest with the pharmaceutical industry, there would not be 
any clinically relevant benefits from using glucosamine to treat 
osteoarthrosis.
In another systematic review, Black et al.31 reached 
inconsistent conclusions regarding the clinical improvements 
among patients using glucosamine sulfate and chondroitin, 
with only modest effects on pain and function. Their 
evaluation on joint space reduction produced data that were 
more consistent, but without clinical relevance. In analyzing 
glucosamine sulfate alone, significant improvements in pain, 
function and joint space reduction were observed, but the 
clinical significance of these data could not be defined with any 
clarity. Also in this study, the cost effectiveness relationship of 
the treatment could not be clearly demonstrated.
Recently, Wandel et al.24 published a meta-analysis in 
the British Medical Journal that included 3,803 patients 
distributed in 10 large RCTs. All the studies included had 
at least 100 patients in each intervention (glucosamine 
sulfate/hydrochloride, chondroitin, glucosamine and 
chondroitin in association and placebo). Compared with 
placebo, glucosamine and chondroitin used separately or in 
association were incapable of diminishing the pain and the 
radiological progression of the arthrosis. The differences found 
were small and clinically irrelevant. The authors concluded 
that neither public healthcare administrators nor health 
insurance plans should be held responsible for the costs of 
using such medications. Moreover, these authors also stated 
that new prescriptions for glucosamine chondroitin should be 
discouraged in clinical practice.
Among the clinical trials, Clegg et al.22 published a 
multicenter RCT named GAIT, which compared the use of 
glucosamine, chondroitin, glucosamine and chondroitin in 
association, celecoxib and placebo for clinical treatment of 
patients with knee osteoarthrosis. The clinical trial evaluated 
1,583 patients in 13 research centers in the United States. 
As the primary outcome, the study found that there was a 
20% decrease in pain on the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) and OMERACT-
OARSI. The general result after 24 weeks of follow-up showed 
that glucosamine and chondroitin separately or in association 
did not differ from placebo or celecoxib with regard to 
overall pain control. However, in analyzing the subgroups, 
the association between glucosamine and chondroitin was 
shown to be effective for diminishing pain in patients with 
moderate to severe gonarthrosis. However, given that the data 
were not generated for analyses on any particular subgroup, 
the results extracted from a subgroup should only serve to 
generate hypotheses for future research. Some authors have 
questioned the results from this study and have argued that in 
the USA, glucosamine and chondroitin are substances that are 
considered to be dietary supplements and do not undergo rigid 
quality control. Nevertheless, for the GAIT study, the quality 
control was done by the Food and Drug Administration (FDA).
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Final remarks
We conclude that in the light of the best evidence currently 
available, use of glucosamine sulfate/hydrochloride and 
chondroitin do not produce clinically relevant benefits for 
patients with knee and hip osteoarthrosis (level I evidence 
and grade A recommendation). Future studies with appropriate 
methodology are needed in order to elucidate this issue.
Conflicts of interest
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